Review

cardiac performance analysis software (Philips Healthcare)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Philips Healthcare cardiac performance analysis software
Cardiac Performance Analysis Software, supplied by Philips Healthcare, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/analysis+software/angiography+coronary+quantitative/pm42320977-51-19-15
Average 86 stars, based on 1 article reviews

cardiac performance analysis software - by Bioz Stars, 2026-10

86/100 stars

Images

Magnetic Resonance Imaging:

Article Title: Interrogating cognitive and neural group variation in childhood: Examples in adolescent brain cognitive development and Oregon attention-deficit/hyperactivity disorder-1000 cohorts.
Article Snippet: .. Children completed high-resolution T1- and T2-weighted structural MRI and diffusion MRI using scanners from GE Healthcare (Waukesha, Wisconsin), Siemens Healthcare (Erlangen, Germany), or Philips Healthcare (Andover, Massachusetts). ..

Diffusion-based Assay:

Software:

Article Title: Association between baseline blood pressure variability and cardiac mechanics and electrophysiology after acute exposure to high altitude.
Article Snippet: Echocardiographic examination was conducted using an ultrasound machine (CX50, Philips Ultrasound System, Andover, MA, USA) to obtain LV data. .. Images were digitally saved for subsequent offline analysis with software (QLAB 10.5, Philips Healthcare, Andover, MA, USA). .. Echocardiographic examination was conducted using an ultrasound machine (CX50, Philips Ultrasound System, Andover, MA, USA) to obtain LV data.

Article Title: The Intelligent Probe – Redefining Transesophageal Echocardiography in the Era of Artificial Intelligence
Article Snippet: .. 4D LV Analysis is a vendor-independent software from Tomtec (now part of Philips Ultrasound Workspace), available on both TEE and TTE which allows semi-automated measurement of LV function including LV Volumes, LV mass, EF, and Myocardial strain. .. 4D LV Analysis is a vendor-independent software from Tomtec (now part of Philips Ultrasound Workspace), available on both TEE and TTE which allows semi-automated measurement of LV function including LV Volumes, LV mass, EF, and Myocardial strain.

Article Title: Study on the application of serological indicators combined with ultrasonic cardiogram in predicting recurrence of radiofrequency ablation in atrial fibrillation patients
Article Snippet: .. In the 3-dimensional mode, QLAB analysis software (Philips Healthcare, Andover) was applied to place 5 marker points at the top of the left ventricle and left atrium, as well as the mitral annular. ..

Imaging:

Article Title: Multimodal deep learning with missing data robustness for enhanced early diagnosis of coronary artery disease using CCTA, clinical, and ECG data
Article Snippet: .. The internal dataset comprises coronary CT angiography images obtained from three machines: the Philips IQon Spectral CT and the United Imaging UCT760 128-slice. .. The external validation dataset includes images from two machines: the Philips Brilliance 256-slice iCT and the United Imaging UCT860 128-slice (Appendix ).

Marker:

Similar Products

Image Search Results

$Physical attributes of naturally aged mice were enhanced following mGFD‐CD3 treatment. (A) Maximal walking speed, treadmill endurance, hanging endurance, and grip strength of naturally aged mice treated with mCD3 or mGFD‐CD3 were recorded at 6 months after the first infusion ( n = 5 mice per condition). (B) H&E staining of gastrocnemius collected from mice treated with mCD3 or mGFD‐CD3, sampled 6 months after the first infusion. Scale bar, 50 μm. Relative cell areas in the gastrocnemius were quantified using Image J ( n = 5 mice per condition). (C) Representative micro‐CT images of the distal femurs of the mice treated with mCD3 or mGFD‐CD3 at 6 months after the first infusion. The relative bone volume fraction (BV/TV) of cancellous bone in the distal femur was quantified for each sample and analyzed by Imaris image analysis software ( n = 5 mice per condition). (D) The percentages of total lean mass and total adipose mass and the adipose mass/lean mass ratio of naturally aged mice treated with mCD3 or mGFD‐CD3 6 months after the first infusion were recorded using InAlyzer software ( n = 5 mice per condition). (E) (left) Micro‐CT images of SAT and bone of the naturally aged mice treated with mCD3 or mGFD‐CD3 were recorded 6 months after the first infusion. Green, SAT; red, bone. (right) Quantification of the adipose tissue of mice based on the micro‐CT images ( left ). Data were normalized to mouse body weight ( n = 5 mice per condition). (F) Basal glucose levels after 12 h of starvation in mice treated with mCD3 or mGFD‐CD3 at 6 months after the first infusion ( n = 5 mice per condition). (G) ( upper ) Levels of glucose before (0 min) and after the intraperitoneal administration of glucose (2 g per kg body weight) (samples as per in (f)). ( lower ) Area under the curve (AUC) for the results from (g) ( n = 5 mice per condition). The mouse experiments are representative results from two independent experiments. Data are presented as mean ± SD and analyzed by one‐way ANOVA followed by Tukey's multiple comparisons test (A–G). * p ≤ 0.05; ** p ≤ 0.01.$

Journal: Aging Cell

Article Title: uPAR ‐Targeting T Cell Engager Exerts Senolytic Effects in Mice and Non‐Human Primates With Serum Aminotransferase Activity as a Safety Monitor

doi: 10.1111/acel.70742

Figure Lengend Snippet: Physical attributes of naturally aged mice were enhanced following mGFD‐CD3 treatment. (A) Maximal walking speed, treadmill endurance, hanging endurance, and grip strength of naturally aged mice treated with mCD3 or mGFD‐CD3 were recorded at 6 months after the first infusion ( n = 5 mice per condition). (B) H&E staining of gastrocnemius collected from mice treated with mCD3 or mGFD‐CD3, sampled 6 months after the first infusion. Scale bar, 50 μm. Relative cell areas in the gastrocnemius were quantified using Image J ( n = 5 mice per condition). (C) Representative micro‐CT images of the distal femurs of the mice treated with mCD3 or mGFD‐CD3 at 6 months after the first infusion. The relative bone volume fraction (BV/TV) of cancellous bone in the distal femur was quantified for each sample and analyzed by Imaris image analysis software ( n = 5 mice per condition). (D) The percentages of total lean mass and total adipose mass and the adipose mass/lean mass ratio of naturally aged mice treated with mCD3 or mGFD‐CD3 6 months after the first infusion were recorded using InAlyzer software ( n = 5 mice per condition). (E) (left) Micro‐CT images of SAT and bone of the naturally aged mice treated with mCD3 or mGFD‐CD3 were recorded 6 months after the first infusion. Green, SAT; red, bone. (right) Quantification of the adipose tissue of mice based on the micro‐CT images ( left ). Data were normalized to mouse body weight ( n = 5 mice per condition). (F) Basal glucose levels after 12 h of starvation in mice treated with mCD3 or mGFD‐CD3 at 6 months after the first infusion ( n = 5 mice per condition). (G) ( upper ) Levels of glucose before (0 min) and after the intraperitoneal administration of glucose (2 g per kg body weight) (samples as per in (f)). ( lower ) Area under the curve (AUC) for the results from (g) ( n = 5 mice per condition). The mouse experiments are representative results from two independent experiments. Data are presented as mean ± SD and analyzed by one‐way ANOVA followed by Tukey's multiple comparisons test (A–G). * p ≤ 0.05; ** p ≤ 0.01.

Article Snippet: 3D image analysis was performed with Imaris image analysis software (version 10.1.0).

Techniques: Staining, Micro-CT, Analysis, Software, Tissue